Associations of diabetes mellitus and hypertension with adherence to continuous positive airway pressure therapy in male patients with obstructive sleep apnea

Shigeko Kojima, PhD1, Ayako Saito, PhD2, Fumihiko Sasaki, MD, PhD3, Masamichi Hayashi, MD, PhD4, Yuki Mieno, MD, PhD5, Hiroki Sakakibara, MD, PhD6, Shuji Hashimoto, PhD2

1 Department of Rehabilitation, Faculty of Health Sciences, Nihon Fukushi University, Handa, Aichi, Japan; 2 Department of Hygiene, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 3 SDB Research Laboratory, Takaoka Clinic, Nagoya, Aichi, Japan; 4 Department of Respiratory Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 5 Tokushige Kokyuki Clinic, Nagoya, Aichi, Japan

Abstract

Objectives: Continuous positive airway pressure (CPAP) is the first line of therapy for obstructive sleep apnea (OSA). Adherence to CPAP, however, is known to be problematic, and its associations with the comorbidities of hypertension and diabetes mellitus have not been sufficiently evaluated. Thus, we investigated the associations of CPAP therapy adherence with comorbidities of hypertension and diabetes mellitus.

Methods: We conducted a retrospective study among 497 male patients with OSA on CPAP therapy. Participants with pretreatment Apnea–Hypopnea Index (AHI) data based on overnight polysomnographic recordings completed a questionnaire. Adherence data for CPAP therapy were collected using a smart card system. We classified CPAP use of ≥4 hours per night and ≥70% of nights as good adherence; other CPAP use was categorized as poor adherence. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for poor adherence to CPAP therapy in the hypertension and diabetes mellitus groups, compared with the no comorbidity group, adjusting for body mass index, duration of CPAP therapy, AHI, and Epworth Sleepiness Scale score.

Results: In the no comorbidity, hypertension, and diabetes mellitus groups, 43.4%, 44.7%, and 56.0%, respectively, had poor adherence to CPAP therapy. Being in the diabetes mellitus group was significantly associated with poor adherence to CPAP therapy (OR=1.86, 95% CI: 1.18–2.92, p=0.007); there was no association for the hypertension group.

Conclusion: Our results indicate that comorbidity of diabetes mellitus is associated with poor adherence to CPAP therapy in male patients with OSA.

Keywords: Obstructive sleep apnea, Continuous positive airway pressure, Adherence, Diabetes mellitus, Hypertension

Introduction

Obstructive sleep apnea (OSA) is a common disorder that is characterized by repetitive upper airway collapse during sleep.1 In 2019, 936 million adults aged 30–69 years were estimated to have mild-to-severe OSA (Apnea–Hypopnea Index [AHI] ≥5/hour) and 425 million adults were estimated to have moderate-to-severe OSA (AHI ≥15/hour) globally. Additionally, in the same year, in Japan, the number of people with OSA was approximately 22 million (32.7% of the population aged 30–69 years), and the number of people with severe OSA (AHI ≥15/hour) was approximately 9.4 million (14.0%).2 OSA leads to increases in metabolic diseases, hypertension, neurological disorders, cardiovascular diseases, and mortality rates.3–11

Continuous positive airway pressure (CPAP) is the first-line therapy for OSA. Maintaining good adherence is essential for fully achieving the therapeutic benefits of CPAP therapy and improving subjective symptoms (such as daytime sleepiness) and high blood pressure.12–16 Several studies have reported low adherence to CPAP therapy among patients with OSA and have pointed out several related factors including AHI, Epworth Sleepiness Scale (ESS) score, snoring, and body mass index (BMI).17,21 However, adherence to CPAP therapy in patients with OSA and other risk factors for cardiovascular disease, including the comorbidities of hypertension and diabetes mellitus, has not been sufficiently evaluated.17,22–24

In the present study, we examined the associations between adherence to CPAP therapy and the comorbidities of hypertension and diabetes mellitus in male patients with OSA, using adherence data recorded using a CPAP device.

Methods

Participants

Our participants were Japanese male patients with OSA who were being treated with CPAP at SDB Research Laboratory, Takaoka Clinic, in August 2011. Of the 998 patients who agreed to participate in the study when they visited the clinic,
705 returned a completed questionnaire (see details below) by mail. Adherence data in the participants' electronic medical records were collected from a smart card, which the participants who returned the questionnaire brought with them when they visited the clinic. The questionnaire collection rate was 71% (705/998), and the adherence data collection rate was 82% (579/705). The mean (standard deviation [SD]) age and AHI of the 705 participants who completed the questionnaire were 56.0 (11.2) years and 49.0 (26.0) events/hour, respectively. The mean (SD) age and AHI of the 579 participants who completed the questionnaire and had valid data on adherence to CPAP therapy were 56.0 (11.1) years and 49.8 (26.0) events/hour, respectively. We excluded 13 patients with missing data on the questionnaire, 35 female patients, and 36 patients with a history of cerebral or cardiovascular disease. Thus, a total of 497 patients with valid data were included in the analysis.

**Survey procedure**

Participants were asked to complete a self-administered questionnaire in August 2011. The questionnaire included the standard diagnostic criteria of the American Academy of Sleep Medicine and a sleep diary. Weight was also self-reported on the questionnaire. The patients' AHI, age, and height before CPAP therapy were obtained from clinical records at SDB Research Laboratory, Takaoka Clinic. BMI was calculated as weight divided by the square of height (kg/m²).

AHI before CPAP therapy was based on overnight polysomnography recordings (Embla N7000, Embla Systems, Inc., Broomfield, CO, USA), which included continuous electroencephalogram, oculogram, electrocardiogram, electromyogram, respiratory channels including nasal and oronasal airflow, thoracic and abdominal respiratory movements, and pulse oximetry, snoring, position, and video monitoring. Sleep stages and respiratory events were scored using the standard diagnostic criteria of the American Academy of Sleep Medicine and a criterion published by registered polysomnogram technicians. Participants in this study were male patients with OSA who had an AHI ≥20/hour or 5/hour to <20/hour and a failed oral appliance. Participants were not included if the oral appliance worked.

We used the self-administered questionnaire to ask participants with OSA about their medical history, including their history of the following comorbidities: hypertension, diabetes mellitus, cardiovascular disease, cerebral disease, arrhythmia, and pulmonary hypertension. For each participant, data on adherence to CPAP therapy were obtained for 1 month following the date the questionnaire was completed; these data were objectively measured using a CPAP device with a smart card system. Adherence to CPAP therapy was defined as the proportion of nights CPAP was used and the median number of hours of nightly CPAP use. We classified CPAP use of ≥4 hours per night and ≥70% of nights as good adherence, and other CPAP use was classified as poor adherence.

**Data analyses**

Of the 497 participants, 103 had hypertension (hypertension group), 125 had diabetes mellitus (diabetes mellitus group), and 288 had no comorbidities (no comorbidity group). A total of 32 patients with both hypertension and diabetes mellitus were included in the hypertension and diabetes mellitus groups. Average values of age, duration of CPAP therapy, BMI, AHI, and ESS score were compared across the hypertension, diabetes mellitus, and no comorbidity groups using independent samples t-tests. Logistic regression models were used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for poor adherence to CPAP therapy in the hypertension group and diabetes mellitus group, compared with the no comorbidity group, adjusting for age, duration of CPAP therapy, BMI, AHI, and ESS score. The level of statistical significance was set at 0.05. The analyses were performed using IBM SPSS, Version 23 for Windows (IBM Japan Ltd., Tokyo, Japan).

**Ethical considerations**

All participants provided informed consent in writing before completing the self-administered questionnaire. This study was approved in November 2010 by the Ethical Review Board for Epidemiological and Clinical Studies of the Fujita Health University School of Medicine, Aichi, Japan (10-198), and was conducted in accordance with the Declaration of Helsinki.

**Results**

The characteristics of the participants in the hypertension, diabetes mellitus, and no comorbidity groups are shown in Table 1. Compared with the values in the no comorbidity group, the average values of age and BMI in the hypertension group and age in the diabetes mellitus group were significantly higher. The average value of BMI was significantly lower in the diabetes mellitus group than in the no comorbidity group (Table 1). The percentages with poor adherence to CPAP therapy in the no comorbidity, hypertension, and diabetes mellitus groups were 43.4%, 44.7%, and 56.0%, respectively. The ORs and 95% CIs for poor adherence to CPAP therapy in the diabetes mellitus and hypertension groups are shown in Table 2. After adjusting

| Characteristic | No comorbidity group (n=288) | Hypertension group (n=103) | p value | Diabetes mellitus group (n=288) | p value |
|---------------|-----------------------------|---------------------------|---------|---------------------------------|---------|
| Age (SD), years | 55.4 (10.8) | 56.2 (9.8) | 0.020 | 59.1 (10.4) | <0.001 |
| Duration of CPAP therapy (SD), years | 2.8 (2.9) | 3.1 (3.3) | 0.392 | 3.0 (2.8) | 0.714 |
| BMI (SD), kg/m² | 28.2 (4.9) | 30.1 (6.2) | 0.001 | 27.8 (4.5) | 0.026 |
| AHI (SD), events/hour | 50.8 (23.3) | 49.9 (25.4) | 0.742 | 50.8 (20.5) | 0.269 |
| ESS score (SD) | 8.7 (4.9) | 8.8 (4.7) | 0.773 | 9.6 (5.5) | 0.164 |
| Habitual sleep (SD), hours | 5.9 (1.0) | 6.0 (1.3) | 0.610 | 5.9 (1.3) | 0.418 |
| Current smoker (%) | 60 (20.8) | 24 (23.3) | 0.601 | 17 (13.6) | 0.083 |
| Non-alcohol drinker (%) | 86 (30.0) | 28 (27.2) | 0.608 | 27 (21.6) | 0.084 |

Abbreviations: OSA, obstructive sleep apnea; BMI, body mass index; AHI, Apnea–Hypopnea Index; ESS, Epworth Sleepiness Scale; CPAP, continuous airway positive pressure; SD, standard deviation
for age, duration of CPAP treatment, BMI, AHI, and ESS score, there was a significant association between being in the diabetes mellitus group and poor adherence to CPAP therapy (OR=1.86, 95% CI: 1.18–2.92, p=0.007). There was no association between being in the hypertension group and poor adherence (OR=1.08, 95% CI: 0.67–1.74, p=0.751) (Table 2).

| Comorbidity (n=497) | Good adherence (n) | Percentage (%) | Poor adherence (OR, 95% CI) |
|---------------------|--------------------|----------------|---------------------------|
| No comorbidities    | 163                | 125            | 43.4                      |
| Hypertension        | 57                 | 46             | 44.7                      | 1.05, 0.67–1.74, p=0.751 |
| Diabetes mellitus   | 55                 | 70             | 56.0                      | 1.66, 1.08–2.92, p=0.007 |

Abbreviations: OSA, obstructive sleep apnea; OR, odds ratio for adherence; CI, confidence interval; CPAP, continuous airway positive pressure

Discussion

Using adherence data recorded using a CPAP device, we found that the comorbidity of diabetes mellitus was significantly associated with poor adherence to CPAP therapy among male patients with OSA and that the comorbidity of hypertension was not significant. There have been several previous studies on diabetes mellitus, hypertension, and adherence to CPAP therapy in patients with OSA. One of these studies showed that hypertension was associated with good adherence to CPAP therapy in non-sleepy patients with moderate-to-severe OSA. Another study reported no association between diabetes mellitus and poor adherence to CPAP therapy in asymptomatic hypertensive patients with OSA. Another of these studies reported that diabetes mellitus was associated with poor adherence to CPAP therapy in patients with severe OSA. Additionally, diabetes mellitus was found not to be predictive of CPAP therapy in patients with cardiovascular disease. Our subjects did not include patients with cardiovascular disease. Our results confirmed the positive association between diabetes mellitus and poor adherence to CPAP therapy in patients with OSA. This finding suggests that, in patients with OSA and diabetes mellitus, health professionals should be aware of poor adherence to CPAP therapy to prevent the development of cardiovascular disease.

There are several possible reasons for the positive association between diabetes mellitus and poor adherence to CPAP therapy in patients. In our study, the patients who had diabetes mellitus may have had poor adherence to diabetes treatment as well as to CPAP therapy, and the patients who had hypertension may have had good adherence to hypertension treatment. Many of the patients with hypertension may have been severely ill and taking antihypertensive drugs; therefore, these patients may have been highly conscious of their treatment. However, the patients who had diabetes mellitus may have had a mild condition, and few were taking medication or insulin injections. Therefore, these patients may have had poor awareness of CPAP therapy. The mean (SD) systolic/diastolic blood pressure in the no comorbidity group, hypertension group, and diabetes mellitus group in this study was 125.3 (11.7)/74.7 (9.6) mmHg, 128.3 (11.4)/74.8 (9.2) mmHg, and 126.8 (12.7)/74.1 (10.5) mmHg, respectively. There was good adherence to hypertension treatment in the hypertension group. There were no data available on HbA1c levels or the type of treatment for the hypertension and diabetes mellitus groups. Therefore, these data should be included in future studies. Many previous studies have reported that the proportion of poor adherence to diabetes mellitus treatment among patients with this disease is high and that improvement requires intervention using a multifactorial approach addressing attitudes regarding therapy, self-efficacy, and health education.

Improvement in adherence to CPAP therapy among patients with OSA who have diabetes mellitus might require the adoption of more comprehensive approaches.

This study has several limitations. Our study was conducted at a single sleep-disordered breathing clinic using a retrospective design. Our subjects were patients who continued medical treatment for OSA and did not include those who discontinued treatment. We were not able to examine discontinuation status of CPAP treatment. We analyzed 579 of the 998 patients with OSA treated at the clinic during the study period; no information on comorbidities or adherence to CPAP was available for the other patients. The effect of this lack of data on our results is unknown. In our study, the questionnaire collection rate was 71%, and the adherence data collection rate was 82%. Questionnaires were collected by mail, and adherence data were collected from smart cards that participants brought with them when they visited the clinic. The collection rate was not high for either type of data, but the mean age and AHI were similar between the 705 participants who completed the questionnaire and the 579 who had valid data on CPAP therapy adherence. All participants in this study were male patients because there were few female patients at the studied clinic. Although the percentage of patients with OSA who are female is not high, an additional study with data on more female subjects would be important.

The adjustment factors were selected on the basis of previous studies; these factors included age, duration of CPAP therapy, BMI, AHI, and ESS score. Including other factors that may have influenced our results (e.g., sleep quality, subjective symptoms, socioeconomic status, level of education, periodic limb movement in sleep index, and residual AHI) might have been helpful. However, this information was not available. The participants in this study were receiving ongoing CPAP therapy, and we could not evaluate patients who stopped CPAP therapy. There is no unified definition of adherence, and several studies have reported the prevalence of poor adherence among people being treated with CPAP as 30%–65%. We used a common definition of poor adherence participants using CPAP for <4 hours per night or <70% of nights.

In conclusion, our results indicate that the comorbidity of diabetes mellitus is associated with poor adherence to CPAP therapy in male patients with OSA.

Acknowledgments

The authors would like to acknowledge the support of the staff and polysomnography technologists at SDB Research Laboratory, Takaoka Clinic. The study was conducted at SDB Research Laboratory, Takaoka Clinic, Nagoya, Japan.
Disclosure statement

The authors declare that there are no financial conflicts of interest.

References

1. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667–89.

2. Benjafeld AV, Ayas NT, Eastwood PR, Heinzner R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tafk S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019; 7: 687–98.

3. Sánchez-de-la-Torre M, Campos-Rodríguez F, Barbé F. Obstructive sleep apnea and cardiovascular disease. Lancet Respir Med 2013; 1: 61–72.

4. Shalhar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O’Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered Breathing and Cardiovascular Disease. Am J Respir Crit Care Med 2001; 163: 19–25.

5. Punjabi NM. The epidemiology of adult obstructive sleep apnoea. Proc Am Thorac Soc 2008; 5: 136–43.

6. Durán J, Esnaola S, Rubio R, Izuzeta Á. Obstructive sleep apnea—hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001; 163: 685–9.

7. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–84.

8. Marin JM, Agustí A, Villar I, Forner M, Nieto D, Carriazo SJ, Barbé F, Vicente E, Wei Y, Nieto FJ, Jelic S. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307: 2169–76.

9. Tahraní AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, Jose B, Piya MK, Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic neuropathy: A novel association in patients with type 2 diabetes. Am J Respir Crit Care Med 2012; 186: 434–41.

10. Harada Y, Oga T, Chin K, Takegami M, Takahashi K, Suni K, Nakamura T, Nakayama-Ashida Y, Minami I, Horita S, Oka Y, Wakamura T, Fukuhara S, Mishima M, Kadotani H. Differences in relationships among sleep apnoea, glucose level, sleep duration and sleepiness between persons with and without type 2 diabetes: Obstructive sleep apnoea and diabetes. J Sleep Res 2012; 21: 410–8.

11. Matsumoto T, Murase K, Tábara Y, et al. Impact of sleep characteristics and obesity on diabetes and hypertension across genders and menopausal status: the Nagahama study. Sleep 2018; 41: 1–10.

12. Jenkinson C, Davies RJ, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 2100–5.

13. Pepperell JC, Ramdassin-Dow S, Crosswhite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204–10.

14. Antic NA, Catcheside P, Buchan C, Hensley M, Naughton MT, Rowland S, Williamson B, Windler S, McEvoy RD. The effect of CPAP in normalizing daytime sleepiness, quality of life, and neurocognitive function in patients with moderate to severe OSA. Sleep 2011; 34: 111–9.

15. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107: 68–73.

16. Craig SE, Kohler M, Nicoll D, Bruton DJ, Nunn A, Davies R, Stradling J. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax 2012; 67: 1096–10.

17. Nasir A, Hupin D, Chomette S, Barthélémy JC, Roche F. Factors influencing adherence to auto-CPAP: An observational monocentric study comparing patients with and without cardiovascular diseases. Front Neurol 2019; 10: 801.

18. Florés M, Martínez-Alonso M, Sánchez-de-la-Torre A, Aldomá A, Galera E, Barbé F, Sánchez-de-la-Torre M, Dalmases M. Predictors of long-term adherence to continuous positive airway pressure in patients with obstructive sleep apnoea and acute coronary syndrome. J Thorac Dis 2018; 10: S124–34.

19. Joachimescu OC, Anthony J, Constantin T, Cavatava MM, McCarver K, Sweeney ME. VAMONOS (Veterans Affairs’ Metabolism, Obstructed and Non-Obstructed Sleep) Study: Effects of CPAP therapy on glucose metabolism in patients with obstructive sleep apnea. J Clin Sleep Med 2017; 13: 455–66.

20. Tsuyumu M, Tsurumoto T, Imura J, Nakajima T, Kojima H. Ten-year adherence to continuous positive airway pressure treatment in patients with moderate-to-severe obstructive sleep apnea. Sleep Breath 2020 (epub ahead of print).

21. Mehtarah M, Bakker JP, Ayas N. Predictors of Continuous Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea. Lung 2019; 197: 115–21.

22. Furukawa T, Suzuki M, Ochiai M, Kawashima H, Yokoyama N, Ishikii T. Long-term adherence to nasal continuous positive airway pressure therapy by hypertensive patients with preexisting sleep apnea. J Cardiol 2014; 63: 281–5.

23. Campos-Rodríguez F, Martínez-Alonso M, Sanchez-de-la-Torre M, Barbe F. Long-term adherence to continuous positive airway pressure therapy in non-sleepy sleep apnea patients. Sleep Med 2016; 17: 1–6.

24. Van Ryswyk E, Anderson CS, Antic NA, et al. Predictors of long-term adherence to continuous positive airway pressure in patients with obstructive sleep apnea and cardiovascular disease. Sleep 2019; 42: za152.

25. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–5.

26. Shiomi T, Sasanabe R. Advances in Diagnosis and Treatment of Sleep Apnea Syndrome in Japan. JMAJ 2009; 52: 224–30.

27. Krîbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dingess DF. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993; 147: 887–95.

28. World Health Organization. Adherence to long-term therapies: evidence for action. <http://www.who.int/chp/knowledge/publications/adherence_report/en/> (Accessed July 20, 2020).

29. Krass I, Schieback P, Dhippayon T. Adherence to diabetes medication: a systematic review. Diabet Med J 2015; 32: 725–37.

30. Iglay K, Cartier SE, Rosen YM, Zarotsky V, Rajapathak SN, Radican L, Tunçel K. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin 2015; 31: 1283–96.

31. Horii T, Momo K, Yaa T, Kabeya Y, Asataka K. Determination of factors affecting medication adherence in type 2 diabetes mellitus patients using a nationwide claim-based database in Japan. PloS One 2019; 14: e0223431.

32. Amer FA, Mohamed MS, Elhur AI, Abdelaziz SI, Elrayah ZA. Influence of self-efficacy management on adherence to self-care activities and treatment outcome among diabetes mellitus type 2. Pharm Pract 2018; 16: 1274.

33. Hashimoto K, Urata K, Yoshida A, Horichi R, Yamaaki N, Yagi K, Arai K. The relationship between patients’ perception of type 2 diabetes and medication adherence: a cross-sectional study in Japan. J Pharm Health Care Sci 2019; 5: 2.
34. Uematsu A, Akashiba T, Kumasawa F, Akahoshi T, Okamoto N, Nagaoka K, Gon Y, Kaneita Y, Uchiyama M, Hashimoto S. Factors influencing adherence to nasal continuous positive airway pressure in obstructive sleep apnea patients in Japan. Sleep Biol Rhythms 2016; 14: 339–49.

35. Tanahashi T, Nagano J, Yamaguchi Y, Kubo C, Sudo N. Factors that predict adherence to continuous positive airway pressure treatment in obstructive sleep apnea patients: A prospective study in Japan. Sleep Biol Rhythms 2012; 10: 126–35.

36. Budhiraja R, Javaheri S, Pavlova MK, Epstein LJ, Omobomi O, Quan SF. Prevalence and correlates of periodic limb movements in OSA and the effect of CPAP therapy. Neurology 2020; 94: e1820–7.

Copyright © 2022 Shigeko Kojima, PhD et al. This is an Open access article distributed under the Terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.